1. |
Coffey S, Cairns BJ, Iung B. The modern epidemiology of heart valve disease. Heart, 2016, 102(1): 75-85.
|
2. |
Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet, 2006, 368(9540): 1005-1011.
|
3. |
潘文志, 周达新, 葛均波. 中国二尖瓣反流患者人群数量的估测. 中国胸心血管外科临床杂志, 2021, 28(5): 495-498.
|
4. |
Dufendach K, Aranda-Michel E, Sultan I, et al. Outcomes of mitral valve surgery for severe ischemic mitral regurgitation. J Card Surg, 2020, 35(2): 390-396.
|
5. |
Zhuge RQ, Hou XP, Qi XL, et al. Clinical features and treatment options for mitral regurgitation in elderly inpatients. J Geriatr Cardiol, 2018, 15(6): 428-433.
|
6. |
Goel SS, Bajaj N, Aggarwal B, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need. J Am Coll Cardiol, 2014, 63(2): 185-186.
|
7. |
Writing Committee Members, Otto CM, Nishimura RA, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol, 2021, 77(4): 450-500.
|
8. |
Debonnaire P, Heyning CMV, Haddad ME, et al. Left ventricular end-systolic dimension and outcome in patients with heart failure undergoing percutaneous mitraclip valve repair for secondary mitral regurgitation. Am J Cardiol, 2020, 126: 56-65.
|
9. |
Pan W, Zhou D, Wu Y, et al. First-in-human results of a novel user-friendly transcatheter edge-to-edge mitral valve repair device. JACC Cardiovasc Interv, 2019, 12(23): 2441-2443.
|
10. |
中国医师协会超声分会超声心动图专业委员会, 中国医师协会心血管内科医师分会结构性心脏病学组. 二尖瓣经导管缘对缘修复的超声心动图操作规范中国专家共识. 中国介入心脏病学杂志, 2022, 30(10): 721-733.
|
11. |
潘文志, 李伟, 周达新, 等. 二尖瓣反流的新分型及相应经导管缘对缘修复手术策略 中华心脏与心律电子杂志, 2024, 12(1): 10-13.
|
12. |
Nishimura RA, Vahanian A, Eleid MF, et al. Mitral valve disease-current management and future challenges. Lancet, 2016, 387(10025): 1324-1334.
|
13. |
中华医学会胸心血管外科分会瓣膜病外科学组. 功能性二尖瓣关闭不全外科治疗中国专家共识. 中华胸心血管外科杂志, 2022, 38(3): 156-163.
|
14. |
Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery?. Eur Heart J, 2007, 28(11): 1358-1365.
|
15. |
Taramasso M, Candreva A, Pozzoli A, et al. Current challenges in interventional mitral valve treatment. J Thorac Dis, 2015, 7(9): 1536-1542.
|
16. |
Head SJ, van Leeuwen WJ, Van Mieghem NM, et al. Surgical or transcatheter mitral valve intervention: complex disease requires complex decisions. EuroIntervention, 2014, 9(10): 1133-1135.
|
17. |
Xu H, Liu Q, Cao K, et al. Distribution, characteristics, and management of older patients with valvular heart disease in China: China-DVD Study. JACC Asia, 2022, 2(3): 354-365.
|
18. |
Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation, 2017, 135(25): e1159-e1195.
|
19. |
Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med, 2018, 379(24): 2307-2318.
|
20. |
Asgar AW, Khairy P. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med, 2011, 365(1): 90.
|
21. |
Smith R, Szerlip M, Lim S, et al. Six-month and one-year outcomes for transcatheter repair in patients with mitral regurgitation from the CLASP study. J Am Coll Cardiol, 2020, 76(17): B3.
|
22. |
Feldman T, Kar S, Elmariah S, et al. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. J Am Coll Cardiol, 2015, 66(25): 2844-2854.
|
23. |
Chiarito M, Pagnesi M, Martino EA, et al. Outcome after percutaneous edge-to-edge mitral repair for functional and degenerative mitral regurgitation: a systematic review and meta-analysis. Heart, 2018, 104(4): 306-312.
|
24. |
Sorajja P, Vemulapalli S, Feldman T, et al. Outcomes with transcatheter mitral valve repair in the United States: an STS/ACC TVT registry report. J Am Coll Cardiol, 2017, 70(19): 2315-2327.
|
25. |
Suri RM, Clavel MA, Schaff HV, et al. Effect of recurrent mitral regurgitation following degenerative mitral valve repair: long-term analysis of competing outcomes. J Am Coll Cardiol, 2016, 67(5): 488-498.
|
26. |
Sorajja P, Moat N, Badhwar V, et al. Initial feasibility study of a new transcatheter mitral prosthesis: the first 100 patients. J Am Coll Cardiol, 2019, 73(11): 1250-1260.
|
27. |
Sorajja P, Gössl M, Babaliaros V, et al. Novel transcatheter mitral valve prosthesis for patients with severe mitral annular calcification. J Am Coll Cardiol, 2019, 74(11): 1431-1440.
|
28. |
Alperi A, Granada JF, Bernier M, et al. Current status and future prospects of transcatheter mitral valve replacement: JACC state-of-the-art review. J Am Coll Cardiol, 2021, 77(24): 3058-3078.
|
29. |
Fukui M, Sorajja P, Gössl M, et al. Left ventricular remodeling after transcatheter mitral valve replacement with tendyne: new insights from computed tomography. JACC Cardiovasc Interv, 2020, 13(17): 2038-2048.
|
30. |
Bapat V, Rajagopal V, Meduri C, et al. Early experience with new transcatheter mitral valve replacement. J Am Coll Cardiol, 2018, 71(1): 12-21.
|
31. |
Del Val D, Ferreira-Neto AN, Wintzer-Wehekind J, et al. Early experience with transcatheter mitral valve replacement: a systematic review. J Am Heart Assoc, 2019, 8(17): e013332.
|
32. |
Barbanti M, Piazza N, Mangiafico S, et al. Transcatheter mitral valve implantation using the highlife system. JACC Cardiovasc Interv, 2017, 10(16): 1662-1670.
|
33. |
Schneider LM, Worthley S, Nickenig G, et al. 1-Year outcomes following transfemoral transseptal transcatheter mitral valve replacement: the highlife TSMVR feasibility study. JACC Cardiovasc Interv, 2023, 16(23): 2854-2865.
|
34. |
Maisano F, Benetis R, Rumbinaite E, et al. 2-year follow-up after transseptal transcatheter mitral valve replacement with the cardiovalve. JACC Cardiovasc Interv, 2020, 13(17): e163-e164.
|
35. |
Nunes Ferreira-Neto A, Dagenais F, Bernier M, et al. Transcatheter mitral valve replacement with a new supra-annular valve: first-in-human experience with the altavalve system. JACC Cardiovasc Interv, 2019, 12(2): 208-209.
|
36. |
Goel SS, Zuck V, Christy J, et al. Transcatheter mitral valve therapy with novel supra-annular altavalve: first experience in the United States. JACC Case Rep, 2019, 1(5): 761-764.
|
37. |
Webb JG, Murdoch DJ, Boone RH, et al. Percutaneous transcatheter mitral valve replacement: first-in-human experience with a new transseptal system. J Am Coll Cardiol, 2019, 73(11): 1239-1246.
|
38. |
Webb J, Hensey M, Fam N, et al. Transcatheter mitral valve replacement with the transseptal EVOQUE system. JACC Cardiovasc Interv, 2020, 13(20): 2418-2426.
|
39. |
Alperi A, Dagenais F, Del Val D, Bernier M, et al. Early experience with a novel transfemoral mitral valve implantation system in complex degenerative mitral regurgitation. JACC Cardiovasc Interv, 2020, 13(20): 2427-2437.
|
40. |
Modine T, Vahl TP, Khalique OK, et al. First-in-human implant of the cephea transseptal mitral valve replacement system. Circ Cardiovasc Interv, 2019, 12(9): e008003.
|
41. |
中国医师协会心血管内科医师分会结构性心脏病专业委员会. 中国经导管主动脉瓣置换术临床路径专家共识(2021 版). 中国介入心脏病学杂志, 2022, 30(1): 7-16.
|